PHKA1 Knockout cell line (TPC-1)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

PHKA1 (phosphorylase kinase regulatory subunit alpha 1) encodes the skeletal muscle alpha subunit of phosphorylase kinase, a multisubunit enzyme complex that regulates glycogen breakdown. The alpha subunit has a regulatory role within the complex, whose catalytic gamma subunit phosphorylates glycogen phosphorylase to promote glycogenolysis. PHKA1 therefore contributes to regulation of muscle glycogen metabolism, and defects in this gene cause X-linked muscle glycogen storage disease.

Papillary thyroid carcinoma is represented by TPC-1, a human thyroid cancer cell line established from a thyroid tumor. The cells are classified as a human papillary thyroid carcinoma model and carry the characteristic RET/PTC1 rearrangement resulting from fusion of RET with CCDC6. TPC-1 is widely used for studies of thyroid cancer biology and RET-associated oncogenic signaling.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.